



October 19, 2022

✓ **BSE Limited**

Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001

National Stock Exchange of India Ltd.,

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051

Dear Sir/Madam,

**Re: Disclosure pursuant to Regulation 30 of SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015**

Subject: Update on the Company's Biotech manufacturing facility

The U.S. FDA conducted a Prior-Approval Inspection at Lupin's Biotech manufacturing facility in Pune, India in October 2022. The inspection concluded with the issuance of a Form 483 with seventeen observations. We are committed to addressing the concerns raised by the U.S. FDA expeditiously.

The Company does not believe that the 483 letter will have an impact on the existing revenues from operations of this facility.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The above is for your information and dissemination.

Thanking you,

FOR LUPIN LIMITED

**R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)**